In 1988, it was found that abnormalities in the lipid metabolism were responsible for the clinical features of SLS.2 The enzyme involved, fatty aldehyde dehydrogenase (FALDH), is part of the fatty alcohol nicotinamide adenine dinucleotide oxidoreductase complex and catalyses oxidation of many different medium‐ and long‐chain fatty aldehydes, derived from fatty alcohols, into fatty acids. This evidence concerns the gene ALDH3A2 and Sjogren-Larsson syndrome.